Welcome to our dedicated page for Sirona Biochem news (Ticker: SRBCF), a resource for investors and traders seeking the latest updates and insights on Sirona Biochem stock.
Sirona Biochem Corp. (SRBCF) delivers cutting-edge biochemical solutions for pharmaceutical research and laboratory applications. This news hub provides investors and industry professionals with essential updates on corporate developments, scientific breakthroughs, and market positioning.
Access authoritative reporting on earnings announcements, regulatory milestones, and strategic partnerships. Our curated collection includes press releases detailing product innovations, research collaborations, and operational updates directly from Sirona Biochem’s leadership team.
Key content focuses on R&D advancements in therapeutic compounds, quality control initiatives, and intellectual property developments. Users will find timely information about patent filings, laboratory reagent innovations, and partnerships with academic institutions.
Bookmark this page for streamlined access to verified SRBCF updates. Check regularly for new developments in biochemical research applications and corporate governance announcements that shape the company’s trajectory in life sciences.
Sirona Biochem (TSX-V: SBM) announced significant operational and financial challenges. The company's recent convertible debenture financing attempt failed to secure sufficient investor participation, following a similar unsuccessful attempt last year. The previously announced investment agreement with Promura GmbH has fallen through, with committed funds never materializing.
Due to financial constraints, Sirona has initiated the liquidation of its subsidiary TFChem, resulting in the permanent closure of laboratory operations. The company is under a cease trade order since March 7, 2025. Additionally, Allergan Aesthetics has withdrawn from the TFC-1067 license agreement originally announced in June 2022. Management is currently evaluating options for potential future development while operating without salaries.
Sirona Biochem Corp. has partnered with Stonegate Healthcare Partners to evaluate its anti-aging ingredient GlycoProteMimTM. Stonegate is a Dallas-based corporate advisory firm providing research-driven business development and investor outreach services. The partnership aims to assess and demonstrate the market potential of GlycoProteMimTM in the global anti-aging skincare industry.
Sirona Biochem Corp (OTC: SRBCF) announced strategic corporate changes following an exclusive global licensing agreement with Allergan Aesthetics. The Board is reviewing all company aspects, including management and project pipeline, aiming for sustainable growth. Additionally, organizational enhancements will occur in Vancouver and Rouen, France, to expedite project development. Sirona plans to strengthen its market presence, enhance investor relations, and pursue up listing opportunities. Continuous updates on these initiatives will be provided throughout 2022.
FAQ
What is the current stock price of Sirona Biochem (SRBCF)?
What is the market cap of Sirona Biochem (SRBCF)?
